Indian pharma company Cipla Limited has launched a point-of-care testing device called Cippoint in India for infectious diseases, non-communicable diseases, and other health conditions.

The device can be used for testing parameters such as cardiac markers, diabetes, infectious diseases, fertility, inflammation, thyroid function, coagulation markers, and metabolic markers.

It is CE IVD approved, which means that the Cippoint device is approved by the European In-Vitro Diagnostic Device Directive.

According to Cipla, Cippoint is an immunofluorescence-based quantitative analyzer, which will enable healthcare professionals to get test results in 3-15 minutes to facilitate a quicker clinical decision-making process.

Achin Gupta — Cipla One India Business CEO said: “Cipla has always been at the forefront of addressing the global diseases burden. We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem.

“This development further strengthens our vision of supporting patients across the healthcare continuum.”

  Achin Gupta, Cipla, Cippoint, India